Intuitive Surgical (NASDAQ:ISRG) Stock Price Down 0.4% Following Insider Selling

Intuitive Surgical, Inc. (NASDAQ:ISRG) dropped 0.4% during trading on Wednesday after an insider sold shares in the company. The company traded as low as $569.49 and last traded at $571.69. Approximately 353,321 shares were traded during trading, a decline of 82% from the average daily volume of 1,947,027 shares. The stock had previously closed at $574.14.

Specifically, Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at $6,955,015. The trade was a 27.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Analyst Ratings Changes

A number of research firms have weighed in on ISRG. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. JPMorgan Chase & Co. upped their price target on Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Truist Financial raised their price objective on Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a report on Friday, January 24th. Mizuho boosted their price target on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Finally, Robert W. Baird lifted their price target on Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Trading Down 0.4 %

The company has a market cap of $203.76 billion, a PE ratio of 91.91, a price-to-earnings-growth ratio of 5.19 and a beta of 1.39. The stock has a fifty day simple moving average of $548.70 and a two-hundred day simple moving average of $507.04.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors have recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA purchased a new stake in shares of Intuitive Surgical in the third quarter valued at $558,807,000. International Assets Investment Management LLC boosted its position in shares of Intuitive Surgical by 49,383.6% in the third quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider’s stock worth $535,788,000 after buying an additional 1,088,415 shares during the period. FMR LLC raised its stake in shares of Intuitive Surgical by 8.3% during the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock valued at $5,389,765,000 after purchasing an additional 838,793 shares during the period. Wilmington Savings Fund Society FSB lifted its holdings in Intuitive Surgical by 15,322.2% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 555,661 shares of the medical equipment provider’s stock worth $272,980,000 after buying an additional 552,058 shares in the last quarter. Finally, Strategic Financial Concepts LLC boosted its holdings in Intuitive Surgical by 50,740.8% in the fourth quarter. Strategic Financial Concepts LLC now owns 312,671 shares of the medical equipment provider’s stock valued at $163,202,000 after purchasing an additional 312,056 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.